Saturday, September 17
Preliminary Program – Day 3
8:00 Welcome Coffee
8:15 Welcome & Introduction
Karin Hartmann (Basel, Switzerland) & Peter Valent (Vienna, Austria)
08:20 Session VIII: Anaphylaxis in Mast Cell Diseases
Chairs: Patrizia Bonadonna (Verona, Italy) & Marek Niedoszytko (Gdansk, Poland)
08:20 Anaphylaxis in Patients with Mast Cell Disorders
Theo Gülen (Stockholm, Sweden)
08:40 Frequency and Management of Peri-Operative Anaphylaxis in Mastocytosis
Hanneke Oude Elberink (Groningen, The Netherlands)
09:00 Clinical and Flow Cytometric Characteristics of Patients with Primary Mast Cell Disorders with Anaphylaxis
Vito Sabato (Antwerp, Belgium)
09:20 Multidisciplinary Personalized Treatment of Patients with Mastocytosis
Patrizia Bonadonna (Verona, Italy)
09:40 Coffee Break
09:55 Session IX: Treatment and Evaluation of Response in Non-Advanced Mastocytosis
Chairs: Hanneke Kluin-Nelemans (Groningen, The Netherlands) & Ivan Alvarez-Twose (Toledo, Spain)
09:55 Current Developments in Treatment of Non-Advanced SM
Karin Hartmann (Basel, Switzerland)
10:15 Treatment and Response Assessment in Pediatric Mastocytosis
Melody Carter (Bethesda, MD, USA)
10:35 Assessment of Quality-of-Life in Mastocytosis
Marek Niedoszytko (Gdansk, Poland)
10:55 Treatment Response Criteria in Non-Advanced SM
Frank Siebenhaar (Berlin, Germany)
11:15 Experience with Highly Sensitive KIT D816V mutation analysis in Assessment of Treatment Response in Mastocytosis
Sigurd Broesby-Olsen (Odense, Denmark)
11:35 Coffee Break
11:50 Session X: COVID-19 Infection and Vaccination in Mastocytosis and Mast Cell Activation Syndromes
Chairs: Deepti Radia (London, UK) & Theo Gülen (Stockholm, Sweden)
11:50 COVID-19 Infection in Patients with Mast Cell Disorders
Mariana Castells (Boston, MA, USA)
12:10 Outcome of COVID-19 Vaccinations in Clonal and Non-Clonal MCAS
Matthew Giannetti (Boston, MA, USA)
12:30 Effective Anti-SARS-CoV-2 Immune Response in Clonal Mast Cell Disorders
Olivier Hermine (Paris, France)
12:50 Lunch Break
13:50 Session XI: Hot Topics in Research in Mastocytosis and Mast Cells
Chairs: Gunnar Nilsson (Stockholm, Sweden) & Olivier Hermine (Paris, France)
13:50 The In Vitro Effects of Avapritinib and Nintedanib on Neoplastic Cells in Patients with SM and SM-AHN
Lina Degenfeld-Schonburg (Vienna, Austria)
14:00 Serum Levels of TIM-3 and GAL-9 in Mastocytosis
Martina Konantz (Basel, Switzerland)
14:10 Stimulation of Mast Cells by Tumor-Derived Extracellular Vesicles
Yoseph Mekori (Tel-Aviv, Israel)
14:20 Altered Innate Immune Profile in Blood of SM Patients
Alba Perez-Pons & Andres Garcia-Montero (Salamanca, Spain)
14:30 Expression and Modulation of Siglec Molecules on Normal and Neoplastic Mast Cells and Basophils
Dubravka Smiljkovic (Vienna, Austria)
14:40 Prevalence of Clonal Mast Cell Disorders in the Veneto Region in Italy
Roberta Zanotti (Verona, Italy)
14:50 Involvement of the Hedgehog Pathway in Advanced SM
Leila Maouche Chretien (Paris, France)
15:00 Coffee Break
15:15 Session XII: Perspectives and Wishes of Patient Support Groups in Mast Cell Disorders
Chairs: Karin Hartmann (Basel, Switzerland) & Cem Akin (Ann Arbor, MI, USA)
15:15 Perspectives of European Patient Support Groups
Jessica S. Hobart (UK) & Nicole Hegmann (Germany)
15:30 Perspectives of US Patient Support Groups
Susan Jennings (USA) & Valerie M. Slee (USA)
15:45 Perspectives of Australian Patient Support Groups
Kristin Sinclair (Australia) & David Mayne (Australia)
16:00 Wishes of Patients and Open Exchange with All
16:25 Summary of DAY 3 and Closing Remarks
Karin Hartmann (Basel, Switzerland) & Peter Valent (Vienna, Austria)
16:30 End of the Meeting